Company Encyclopedia
View More
name
ISHRS MSCI Israel Capped
EIS.US
News
View More

Check Point Software Unveils Quantum Firewall Software R82.10 to Secure the AI -Driven Enterprise

Check Point Software Technologies Ltd. has launched the Check Point Quantum Firewall Software R82.10, featuring 20 new capabilities to enhance AI adoption, protect distributed environments, and simplify Zero Trust across hybrid networks. The software addresses AI-generated threats, identity abuse, and configuration drift, offering improved visibility, control, and protection. It integrates with Check Point's AI security stack and will be available for download later this month. A webinar on securing AI transformation will be held on December 4th.

marketscreener·
US
CHKP
+2.48%
marketscreener·
US
CHKP
+2.48%

UK pro-Palestinian activist says raid on Elbit factory was about destroying weapons

A UK pro-Palestinian activist, Charlotte Head, is on trial for a raid on Israeli defence firm Elbit's factory, aiming to destroy weapons. She denies using violence, despite charges of aggravated burglary and violent disorder. The trial involves six defendants, with one accused of causing grievous bodily harm. Head claims the action was a last resort after other efforts failed, and she opposes violence. The trial is ongoing.

Reuters·
US
ESLT
-0.05%
Reuters·
US
ESLT
-0.05%

BUZZ-Cybersecurity co Check Point stabilizes after increased $1.75 bln convertible bond sale

Check Point Software Technologiesstabilized at $191 premarket after raising $1.75 billion through a 0% 5-year convertible bond sale. The initial conversion price is $243.65, a 27.5% premium to the last close. The company plans to use the proceeds for capped call transactions, share repurchases, potential M&A, and new product development. CHKP shares rose 2.1% after falling 3.5% on Wednesday. The stock is up 2% YTD. 14 of 37 analysts rate it as 'strong buy' or 'buy', with a median price target of $225.

Reuters·
US
CHKP
+2.48%
Reuters·
US
CHKP
+2.48%

Teva (NYSE:TEVA) Valuation Check After Strong Q3, Margin Targets and Deleveraging Drive a Sharp Share Price Rebound

Teva Pharmaceutical Industries (NYSE:TEVA) has seen a sharp share price rebound after strong Q3 results, with revenue up 3% and improved debt ratios. The stock returned 36% in one month and 46.9% in three months, reaching $27.83. Analysts suggest Teva is 20% undervalued, with potential growth from biosimilars and innovative drugs. However, its high PE ratio of 44.8x raises caution compared to industry averages. Investors are advised to consider risks and opportunities in Teva's turnaround story.

Simplywall·
US
TEVA
+2.08%
Simplywall·
US
TEVA
+2.08%

Check Point Software Prices $1.75 Billion Convertible Senior Notes Offering

Check Point Software Technologies Ltd. has announced an upsized private offering of $1.75 billion in 0.00% Convertible Senior Notes due 2030, increased from $1.5 billion. The offering is for qualified institutional buyers, with an option for an additional $250 million. The notes are senior unsecured obligations, maturing on December 15, 2030. Proceeds will be used for capped call transactions, share repurchases, and general corporate purposes, including potential mergers and acquisitions.

Reuters·
US
CHKP
+2.48%
Reuters·
US
CHKP
+2.48%
© 2025 Longbridge｜Disclaimer